Life Science REIT PLC Sale of Lumen House, Harwell Oxford (2798V)
01 Dezembro 2023 - 4:00AM
UK Regulatory
TIDMLABS
RNS Number : 2798V
Life Science REIT PLC
01 December 2023
1 December 2023
LEI: 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Sale of Lumen House, Harwell Oxford
Life Science REIT (LSE: LABS), the real estate investment trust
focused on UK life sciences properties, announces that it has
completed the sale of Lumen House for GBP7.65 million to Harwell
Science and Innovation Campus, a joint venture between Brookfield
and the UK Atomic Energy Authority together with the Science and
Technology Facilities Council. The disposal price represents a 5.6%
net initial yield and is 2% ahead of June 2023 book value.
Lumen House is located on the Harwell Campus in Oxford and with
the current occupier soon to vacate the building, presents an
attractive development opportunity for the purchaser whilst
providing Life Science REIT with additional flexibility to progress
more transformational opportunities. These include delivering fully
fitted laboratories at Cambourne Park Science and Innovation Campus
in Cambridge and progressing the development of Oxford Technology
Park.
Lumen House was acquired in December 2021 for GBP7.05 million
with the disposal achieving a 9% uplift on the acquisition
price.
Simon Farnsworth, Managing Director of Ironstone Asset
Management, the Company's Investment Adviser, said : "The economic
environment in which Life Science REIT acquired Lumen House is very
different to the one we face today and the Company is making
capital allocation decisions which reflect that. By realising value
from this investment now, we can better focus our efforts and the
Company's capital on larger scale opportunities where we are
already on site and where we believe that the return profile is
more attractive. The fully fitted laboratory initiative at
Cambourne Park Science and Technology Campus is a great example of
that approach."
END
Enquiries:
+44 20 3011
Ironstone Asset Management - Investment Adviser 2160
Simon Farnsworth, Managing Director
Simon.farnsworth@ironstoneam.com
Joanna Waddingham, Head of Investor Relations
and Corporate Affairs
Joanna.Waddingham@ironstoneam.com
Link Company Matters Limited - Company Secretary
labs_cosec@linkgroup.co.uk
Panmure Gordon (UK) Limited - Joint Corporate +44 20 7886
Broker 2500
Alex Collins / Tom Scrivens
Jefferies International Limited - Joint Corporate +44 20 7029
Broker 8000
Tom Yeadon / Andrew Morris / Oliver Nott /
Harry Randall
+44 20 7397
G10 Capital Limited - AIFM 5450
Maria Baldwin
+44 20 7466
Buchanan - Financial PR 5000
Mark Court / Henry Wilson / Verity Parker
LifeSciencereit@buchanan.uk.com
Notes to editors
Life Science REIT plc is a specialist property business focused
on the UK's growing life science sector. The Company's portfolio of
assets is located across the "Golden Triangle" of research and
development hubs in Oxford, Cambridge and London's Knowledge
Quarter and its strategic vision is to become the property provider
of choice for life science companies in the UK.
Life Science REIT is addressing the acute demand-supply
imbalance for laboratory space in the "Golden Triangle", which is
characterised by low vacancy rates and prime rental increases. The
UK life science sector itself is benefiting from a buoyant early
stage funding environment, driving demand for laboratory space.
The Company's diverse portfolio of assets ranges from a 20-acre
science park currently under development through to fully let
buildings, with an important part of the Company's strategy being
the conversion of existing properties to laboratory space.
The Company's investment policy is focused on capital growth
whilst also providing a growing level of income.
Life Science REIT trades on the Main Market of the London Stock
Exchange under the ticker LABS.
Further information is available at
https://lifesciencereit.co.uk . To sign up for email alerts, please
visit https://lifesciencereit.co.uk/investors/ .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DISNKKBNABDDODN
(END) Dow Jones Newswires
December 01, 2023 02:00 ET (07:00 GMT)
Life Science Reit (LSE:LABS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Life Science Reit (LSE:LABS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024